Teva Pharmaceuticals

Alvotech has settled with Regeneron, clearing a path for its biosimilar AVT06 (aflibercept) to potentially enter the U.S. market in late 2026, pending FDA approval. This agreement, alongside a partnership with Teva Pharmaceuticals, follows AVT06’s recent marketing approvals in the UK, Japan, and the EEA. Clinical studies have confirmed AVT06’s high degree of similarity to Eylea®, positioning it as a more affordable alternative for retinal diseases.

Teva Pharmaceuticals presented positive real-world data on AUSTEDO XR® for tardive dyskinesia (TD) at the 2025 Psych Congress. A survey of 209 TD patients showed significant treatment satisfaction, with over 94% reporting movement improvement and over 89% expressing high overall satisfaction. Furthermore, 77% reported improved social comfort and emotional well-being, and 96% found the medication easy to take. 96% of patients expressed interest in continuing treatment.